When most people hear about GLP-1 medicines for diabetes or weight loss, they think of injections
Agenda Co-chairs Dr Luz de Regil Director, Department of Nutrition and Food Safety, WHO and Dr Kirsten Bibbins Domingo Editor-in-Chief, JAMA Moderator Dr Gaya Manori Gamhewage, Director, Department of Communication, WHO Welcoming Dr Luz De Regil Director NFS, WHO and Dr Kirsten Bibbins-Domingo, Editor-in-Chief, JAMA Presentation: WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults Dr Francesca Celletti, Senior Advisor Obesity, Department of Nutrition and Food Safety, WHO and Dr
Workforce analysis of psychological practice with older adults: Growing crisis requires urgent action
After 24 h, cells were collected and stained for flow cytometry
Caffeine can impact sleep, increase your heart rate, and potentially raise your blood pressure, Massey said
Tirzepatide: Which One Is Right for Me